Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

ClinicalTrials.gov ID: NCT07491445

Public ClinicalTrials.gov record NCT07491445. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

Study identification

NCT ID: NCT07491445
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Revolution Medicines, Inc.; Industry
Enrollment: 900 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 8, 2026
Primary completion: May 31, 2028
Completion: Feb 28, 2029
Last update posted: Aug 26, 2026

2026 – 2029

United States locations

U.S. sites: 15
U.S. states: 13
U.S. cities: 15

Facility	City	State	ZIP	Site status
Honor Health Research Institute	Scottsdale	Arizona	85258	Recruiting
University of California San Francisco	San Francisco	California	94158	Recruiting
H Lee Moffitt Cancer Center and Research Institute	Tampa	Florida	33612	Recruiting
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center	Baltimore	Maryland	21287	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Comprehensive Cancer Centers of Nevada	Henderson	Nevada	89052	Active, not recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
University of Cincinnati Cancer Center	Cincinnati	Ohio	45219	Recruiting
Taylor Cancer Research Center	Maumee	Ohio	43537	Active, not recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
SCRI - Texas Oncology Dallas	Dallas	Texas	95246	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Huntsman Cancer Institute	Salt Lake City	Utah	84112	Recruiting
Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting
Virginia Mason Medical Center	Seattle	Washington	98101	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07491445, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 26, 2026 · Synced Sep 11, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07491445 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →